Hyperbaric Treatment of Traumatic Brain Injury (TBI)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2013 by Jupiter Medical Center
Sponsor:
Collaborator:
Jupiter Medical Center
Information provided by (Responsible Party):
Barry Miskin, MD, Jupiter Medical Center
ClinicalTrials.gov Identifier:
NCT01847755
First received: April 30, 2013
Last updated: May 6, 2013
Last verified: May 2013
  Purpose

This study is designed to test the hypothesis that patients with Traumatic Brain Injury (TBI)treated with Hyperbaric (HBO) will show improvement in function and an increased blood flow as evidenced by single-photon emission computerized tomography (SPECT) scan. Improvement is evidenced by increase in number of pixels on SPECT Scan and increased brain metabolism. Improvement may also be identified via cognitive assessments administered by Jupiter Medical Center Research Department.


Condition Intervention Phase
Traumatic Brain Injury
Drug: Oxygen at 1.5 ATA (atmospheres absolute).
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 1 Study of Hyperbaric Treatment of Traumatic Brain Injury

Resource links provided by NLM:


Further study details as provided by Jupiter Medical Center:

Primary Outcome Measures:
  • Improved cognitive function [ Time Frame: At 120 Hyperbaric Treatments (5 treatments a week) over approximately 24 weeks with a follow up 3 months post treatment ] [ Designated as safety issue: No ]
    Improved (increase number of pixels on SPECT scan) blood flow to brain, improved (cognitive assessment score) cognitive function, improvement in symptoms and Evaluation of Cognitive Impairment score.The time points for evaluation of cognitive status and single-photon emission computerized tomography (SPECT) scan will be at at 40,80,120 Hyperbaric(HBO)treatments. Treatment will occur 5 times per week for approximately 24 weeks with another follow up 3 months post treatment. This will provide all data points for outcome measure.


Estimated Enrollment: 100
Study Start Date: April 2013
Estimated Study Completion Date: April 2015
Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 120 Hyperbaric treatments at 1.5 ATA
Patient receives 120 treatments of Hyperbaric at 1.5 ATA. Non randomized trial. Pt will have cognitive assessments and Spect scans at various treatment points. Oxygen is at 1.5 atmospheric pressure.
Drug: Oxygen at 1.5 ATA (atmospheres absolute).
Each patient will undergo 5 times-a-week Hyperbaric treatments to 1.5 ATA (atmospheres absolute) for up to 120 treatments. Treatment in hyperbaric chamber will be approximately 60 minutes. At specified intervals 40,80,120, patient will be assessed by Spect scan and cognitive assessments to provide outcome measure data. Pt will have a 3 month post treatment follow up assessment.
Other Name: 02 or Oxygen

Detailed Description:

Patients with Traumatic Brain Injury (TBI)have abnormal findings including hemorrhagic cortical contusions or petechial or foci of altered signal that represents white matter injury. MRI, CT or SPECT scans showing changes consistent with Traumatic Brain Injury (TBI)and or medical history of Traumatic Brain Injury (TBI)as evidenced by medical records will be screened for treatment with Hyperbaric. Each patient will undergo 5 times-a-week Hyperbaric treatments to 1.5 atmospheres absolute(ATA).

Each patient will have a SPECT scan, cognitive assessment, and physician evaluation prior to first treatment and after 40, 80, and 120 treatments to document progress of the treatment (Harch et al, 2012). Cognitive assessment will include the Trail Making Test Parts A and B. Patient will be seen by physician to assess level of disability at each interval; the United States Department of Veteran Affairs' Evaluation of Cognitive Impairment and Subjective Symptoms (VAECI) (2012) tool will be utilized during the physician's evaluation as an objective measure of the patient's level of disability.

Hyperbaric treatments may be adjusted for patient comfort. If the SPECT scan, cognitive assessment and physician evaluation show improvement after 40 treatments, another 40 Hyperbaric(HBO)treatments will be administered. Treatments will be discontinued after a 40 session interval if the SPECT scan, cognitive assessment and physician evaluation show no improvement. The patient will also have a SPECT scan and cognitive assessment follow up 3 months after final Hyperbaric(HBO) treatment.The time points for evaluation of cognitive status and single-photon emission computerized tomography (SPECT) scan will be at at 40,80,120 Hyperbaric(HBO)treatments. Treatment will occur 5 times per week for approximately 24 weeks with another follow up 3 months post treatment. This will provide all data points for outcome measure.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All Stage Traumatic Brain Injury (TBI)as demonstrated by loss of consciousness due to the injury that is a minimum of 1 year old
  • Age ≥18 years
  • Eastern Cooperative Oncology Group (ECOG) 0-2
  • Women: Negative pregnancy test: If sexually active, women will take contraceptive measures for the duration of the treatments. Medically acceptable contraceptives include: 1) surgical sterilization (such as tubal ligation, hysterectomy, 2) approved hormonal contraceptives (such as birth control pills, patches, implants or injections), 3) barrier methods (such as a condom or diaphragm) used with a spermicide, or 4) an intrauterine device (IUD).
  • Subjects capacity to give legally effective consent (patient is alert and oriented x3).
  • Signed consent form approved by the Institutional Review Board prior to patient entry
  • History of lung disease (e.g. bronchitis, asthma) requires chest x-ray prior to inclusion in the study

Exclusion Criteria:

  • Untreated Pneumothorax

    • Anti-metabolites/chemotherapeutic agents (is used currently)
    • Mafenide Acetate (sulfamylon): antibacterial drug; peripheral vasodilation Disulfiram (Antabuse)
    • History of spontaneous pneumothorax
    • Seizure Disorder
    • Acute Upper Respiratory Infection
    • Acute High Fever
    • Acute Viral Infection
    • Participation in another experimental trial with active interventions
    • Women who are pregnant or lactating
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01847755

Locations
United States, Florida
Jupiter Medical Center Recruiting
Jupiter, Florida, United States, 33458
Contact: Jeanine Secor, RN,BSN,CCRP    561-263-5791    jsecor@jupitermed.com   
Contact: Barry Miskin, MD    561 745 7789    barrymiskin@me.com   
Principal Investigator: Barry Miskin, MD         
Sponsors and Collaborators
Barry Miskin, MD
Jupiter Medical Center
Investigators
Principal Investigator: Barry Miskin, MD Jupiter Medical Center
  More Information

No publications provided

Responsible Party: Barry Miskin, MD, Chief of surgery, Medical Director of Wound and Hyperbaric Center, Jupiter Medical Center
ClinicalTrials.gov Identifier: NCT01847755     History of Changes
Other Study ID Numbers: JMC-TBI-001, 117686
Study First Received: April 30, 2013
Last Updated: May 6, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Brain Injuries
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Craniocerebral Trauma
Trauma, Nervous System
Wounds and Injuries

ClinicalTrials.gov processed this record on September 18, 2014